TuHURA Regains Nasdaq Listing, Pivots to Key Cancer Drug Trials

TAMPA, FL – February 27, 2026 – Immuno-oncology firm TuHURA Biosciences, Inc. (NASDAQ: HURA) has successfully regained compliance with Nasdaq's minimum bid price requirement, a crucial milestone that removes a significant cloud of market uncertainty and allows the company to sharpen its focus on an ambitious clinical pipeline aimed at overcoming resistance to cancer therapies.

On February 26, the company announced it had received formal notice from Nasdaq confirming its return to good standing. The notice came after TuHURA's common stock maintained a closing bid price of $1.00 or higher for 11 consecutive business days, from February 10 through February 25, satisfying the exchange's listing rule. The matter is now considered closed, ending a period of financial scrutiny for the Phase 3 biotech company.

"We are pleased to have regained full compliance with Nasdaq's listing standards and continue to remain fully focused on advancing our pipeline of assets," said Dr. James Bianco, President and CEO of TuHURA Biosciences, in a statement. This achievement allows the company to pivot away from administrative hurdles and dedicate its resources to its core mission: developing novel therapeutics for difficult-to-treat cancers.

A Financial Breather After Market Scrutiny

The compliance issue began on January 29, 2026, when TuHURA received a non-compliance notice from Nasdaq. The alert was triggered because the company's stock had traded below the $1.00 minimum for 35 consecutive business days. Such notices can unnerve investors, as failure to regain compliance within a set grace period—which for TuHURA was set to expire in July 2026—can ultimately lead to delisting from the exchange, impacting liquidity and the ability to raise capital.

However, the market has responded positively to the company's recent trajectory. Following the news, TuHURA's stock was trading around $1.62, marking a significant turnaround from its 52-week low of $0.41. Year-to-date, the stock has seen returns of over 114%, reflecting a renewal of investor confidence. With a market capitalization now hovering around $101 million, the company appears to be on more stable footing.

Despite the positive momentum, financial analysts note that the company is navigating the high-cost environment typical of late-stage drug development. Reports indicate TuHURA is burning through cash quickly, a common challenge for clinical-stage biotechs. To address this, the company has an active S-3 shelf registration that could allow it to raise up to $250 million, and it recently secured $15.6 million through a registered direct offering to fund its key programs. Analyst consensus remains optimistic, with a "Moderate Buy" rating and an average price target of $9.00, suggesting significant potential upside if its clinical programs succeed.

Targeting a Formidable Foe: Cancer's Resistance

With the Nasdaq compliance issue resolved, TuHURA is advancing its lead candidate, IFX-2.0, in a pivotal Phase 3 trial. The company's central focus is on a major challenge in modern oncology: the fact that many cancers develop primary or acquired resistance to powerful immunotherapies like checkpoint inhibitors.

IFX-2.0 is designed to tackle this problem head-on in patients with Merkel Cell Carcinoma (MCC), a rare but aggressive form of skin cancer. While checkpoint inhibitors like Keytruda® (pembrolizumab) have become a standard of care, up to half of MCC patients do not respond to this first-line treatment. TuHURA's therapy aims to turn these non-responders into responders.

The therapy is an innate immune agonist administered via direct intra-tumoral injection. It uses a plasmid DNA to make tumor cells express a bacterial protein, Emm55, which acts as a red flag for the immune system. This process is designed to trigger a powerful innate immune response, training the body to recognize and attack the cancer cells, thereby overcoming the tumor's resistance to checkpoint inhibitors.

The ongoing Phase 3 registration trial is a randomized, placebo-controlled study evaluating IFX-2.0 as an adjunctive therapy alongside Keytruda. The trial, which began enrolling patients in June 2025, aims to recruit approximately 118 patients across the United States. It is designed for a potential accelerated approval from the FDA, with the primary endpoint being the Objective Response Rate (ORR).

Expanding the Arsenal with a New Antibody

Beyond MCC, TuHURA is also preparing to launch a Phase 2 study for another promising asset, TBS-2025, which it acquired through a merger with Kineta Inc. in June 2025. This candidate targets a different cancer and employs a distinct mechanism, showcasing the company's multi-pronged strategy.

TBS-2025 is a novel monoclonal antibody that inhibits VISTA, an immune checkpoint highly expressed on myeloid cells in certain cancers. Its first target is a particularly challenging subset of Acute Myeloid Leukemia (AML) characterized by an NPM1 mutation. This mutation is present in about 30% of AML patients, and while it can be associated with a better prognosis initially, relapse is common and outcomes are poor.

In NPM1-mutated AML, VISTA is believed to be a key reason why leukemic cells can evade the immune system. TuHURA's strategy is to combine TBS-2025 with a class of drugs known as menin inhibitors, which are also being developed for this type of AML. Dr. Bianco stated that adding TBS-2025 could "significantly increase the complete remission rate and its duration," addressing a major unmet need where current therapies fall short.

The company filed an Investigational New Drug (IND) application for this study on February 17, 2026, and is targeting an early Q2 2026 start for the Phase 2 trial, with initial results potentially available by the third quarter.

Strategic Vision and Competitive Edge

Regaining Nasdaq compliance is more than just a regulatory victory; it is a foundational step that enables TuHURA to execute its broader corporate strategy. This stability is critical for funding its capital-intensive clinical trials, pursuing potential partnerships, and continuing to build out its pipeline.

The company is also advancing a third platform based on Delta Opioid Receptor technology to develop first-in-class antibody-drug conjugates. This preclinical program aims to prevent T-cell exhaustion and acquired resistance, further reinforcing the company's commitment to solving the immunotherapy resistance puzzle.

By targeting specific, well-defined patient populations where resistance is a known problem—such as non-responders in MCC and relapsed patients in NPM1-mutated AML—TuHURA is positioning its therapies to demonstrate a clear clinical benefit. This focused approach, combined with a strategy of pursuing accelerated approval pathways, could provide a faster route to market if the data proves positive. The recent stock market turbulence appears to be in the rearview mirror, with the road ahead now paved by clinical milestones and the potential to deliver transformative therapies to cancer patients in need.